These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 18384652)
1. Acquired von Willebrand disease: potential contribution of the von Willebrand factor collagen-binding to the identification of functionally inhibiting auto-antibodies to von Willebrand factor: a rebuttal. Guerin V; Ryman A; Velez F J Thromb Haemost; 2008 Jun; 6(6):1051-2. PubMed ID: 18384652 [No Abstract] [Full Text] [Related]
2. Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor. Coleman R; Favaloro EJ; Soltani S; Keng TB J Thromb Haemost; 2006 Sep; 4(9):2085-8. PubMed ID: 16961622 [No Abstract] [Full Text] [Related]
3. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Siaka C; Rugeri L; Caron C; Goudemand J Haemophilia; 2003 May; 9(3):303-8. PubMed ID: 12694522 [TBL] [Abstract][Full Text] [Related]
4. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. van Genderen PJ; Vink T; Michiels JJ; van 't Veer MB; Sixma JJ; van Vliet HH Blood; 1994 Nov; 84(10):3378-84. PubMed ID: 7949092 [TBL] [Abstract][Full Text] [Related]
5. Acquired von Willebrand's syndrome in the course of Waldenström's disease. Mazurier C; Parquet-Gernez A; Descamps J; Bauters F; Goudemand M Thromb Haemost; 1980 Dec; 44(3):115-8. PubMed ID: 6781094 [TBL] [Abstract][Full Text] [Related]
6. A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome. Franchi F; Biguzzi E; Stufano F; Siboni SM; Baronciani L; Peyvandi F Thromb Res; 2014 Dec; 134(6):1316-22. PubMed ID: 25300810 [TBL] [Abstract][Full Text] [Related]
7. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies. Sucker C; Michiels JJ; Zotz RB Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364 [TBL] [Abstract][Full Text] [Related]
8. Acquired von Willebrand syndrome associated with Hashimoto's thyroiditis and subcutaneous mucosa-associated lymphoid tissue lymphoma. Koyama T; Fujimoto K; Shima M Intern Med; 2013; 52(23):2661-3. PubMed ID: 24292759 [TBL] [Abstract][Full Text] [Related]
9. Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor. Mohri H; Tanabe J; Ohtsuka M; Yoshida M; Motomura S; Nishida S; Fujimura Y; Okubo T Blood Coagul Fibrinolysis; 1995 Sep; 6(6):561-6. PubMed ID: 7578899 [TBL] [Abstract][Full Text] [Related]
10. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management. Mohri H J Thromb Thrombolysis; 2003 Jun; 15(3):141-9. PubMed ID: 14739623 [TBL] [Abstract][Full Text] [Related]
11. Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease. Mannucci PM; Mari D Prog Clin Biol Res; 1984; 150():109-22. PubMed ID: 6431422 [No Abstract] [Full Text] [Related]
12. Acquired von Willebrand disease in myeloproliferative disorders. van Genderen PJ; Leenknegt H; Michiels JJ; Budde U Leuk Lymphoma; 1996 Sep; 22 Suppl 1():79-82. PubMed ID: 8951776 [TBL] [Abstract][Full Text] [Related]
13. [Patient with recurrent gastrointestinal hemorrhage in acquired von Willebrand disease]. Baerlocher GM; Leoncini-Franscini L; Wuillemin WA; Furlan M Ther Umsch; 1999 Sep; 56(9):487-90. PubMed ID: 10517115 [TBL] [Abstract][Full Text] [Related]
14. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Fricke WA; Brinkhous KM; Garris JB; Roberts HR Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998 [TBL] [Abstract][Full Text] [Related]
15. Autoantibody to von Willebrand factor in systemic lupus erythematosus. Soff GA; Green D J Lab Clin Med; 1993 Mar; 121(3):424-30. PubMed ID: 8445290 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of inhibitors in acquired von Willebrand syndrome. Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997 [TBL] [Abstract][Full Text] [Related]
17. Antibody-induced von Willebrand syndrome: inhibition of VIII VWF and VIII AGN with sparing of VIII AHF by the autoantibody. Gazengel C; Prieur AM; Jacques C; Buriot D; Nedellec J; Josso F Am J Hematol; 1978; 5(4):355-63. PubMed ID: 313704 [No Abstract] [Full Text] [Related]
18. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386 [TBL] [Abstract][Full Text] [Related]
19. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options. Favaloro EJ Am J Clin Pathol; 2000 Oct; 114(4):608-18. PubMed ID: 11026108 [TBL] [Abstract][Full Text] [Related]
20. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Xu L; Yang G; Hunter ZR; Treon SP Br J Haematol; 2019 Mar; 184(6):1011-1014. PubMed ID: 29532913 [No Abstract] [Full Text] [Related] [Next] [New Search]